Newsroom

November 2017

• Press release Nov 29, 2017

  Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab (AMG334) in migraine prevention

  Patients with episodic migraine taking erenumab reported significant and meaningful benefits over six months, with reduced migraine days and acute medication use   Fifty percent of patients…
• Featured News Nov 28, 2017

  Biosimilar drugs have the potential to save more than USD 54 billion

  RAND Corporation and the Moran Company issued reports discussing the cost savings associated with biosimilars.

• Press release Nov 27, 2017

  Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®

   New data showed switching moderate-to-severe, symptomatic COPD patients from Seretide®* to Ultibro® Breezhaler® improved lung function and was well tolerated.  The FLASH…
• Press release Nov 20, 2017

  Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children

  Tasigna is the first and only second-generation tyrosine kinase inhibitor approved in the EU for the treatment of Ph+ CML-CP in children  Approval builds on a series of Tasigna regulatory…
• Press release Nov 15, 2017

  Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania

  Objective is to provide patients with rapid cancer diagnostics and appropriate care First focus will be on Ethiopia, Uganda and Tanzania Cancer is on the rise in Africa, with more than 500,000…
• Press release Nov 14, 2017

  Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy

  Presentation of results from the Kisqali® (ribociclib) MONALEESA-7 Phase III trial exclusively studying premenopausal women with HR+/HER2- advanced breast cancer  New MONALEESA-2 analyses…
• Press release Nov 14, 2017

  New data reinforces clinical basis for switching to Sandoz biosimilar medicines

  Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar…
• Press release Nov 13, 2017

  Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants

  Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association…
• 
  Story Nov 13, 2017 Discovery

  Small viruses could accelerate cell and gene therapy research

  Novartis collaborates with Homology Medicines to adapt and refine genome editing technology.

• Press release Nov 13, 2017

  Novartis highlights its differentiated late stage pipeline at the R&D update and investor event

  RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD   AMG 334 has a…
• Press release Nov 12, 2017

  New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure

   Entresto reversed trend of worsening New York Heart Association (NYHA) class - a key measure of the severity of a patient's heart failure symptoms - improving common…
• Press release Nov 11, 2017

  Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases

  Poor patients in Punjab will have access to high-quality  medicines against noncommunicable, chronic diseases thanks to agreement between government and Novartis Access Punjab government will…